Endocannabinoids and Schizophrenia
AbstractThe endocannabinoids anandamide and 2-arachydonoylglycerol (2-AG) are lipids naturally derived from membrane precursors which bind cannabinoid receptors (CB1, CB2). This endocannabinoid system is disturbed in schizophrenia. Indeed, there seems to be an association between schizophrenia and polymorphisms of the CB1 receptor gene. Moreover, CB1 receptors are found in higher density in the prefrontal cortex, hippocampus and basal ganglia of patients with schizophrenia. Similarly, anandamide levels are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, including during the prodromal state, suggesting that they may play a protective role in psychosis homeostasis. Future studies are needed to further explore the role of the endocannabinoid system in the pathophysiology of schizophrenia.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Desfossés, J.; Stip, E.; Bentaleb, L.A.; Potvin, S. Endocannabinoids and Schizophrenia. Pharmaceuticals 2010, 3, 3101-3126.
Desfossés J, Stip E, Bentaleb LA, Potvin S. Endocannabinoids and Schizophrenia. Pharmaceuticals. 2010; 3(10):3101-3126.Chicago/Turabian Style
Desfossés, Joëlle; Stip, Emmanuel; Bentaleb, Lahcen Ait; Potvin, Stéphane. 2010. "Endocannabinoids and Schizophrenia." Pharmaceuticals 3, no. 10: 3101-3126.